EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs can also have activity against NSCLC without EGFR mutations, requiring the identificat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Florent Baty, Sacha Rothschild, Martin Früh, Daniel Betticher, Cornelia Dröge, Richard Cathomas, Daniel Rauch, Oliver Gautschi, Lukas Bubendorf, Susanne Crowe, Francesco Zappa, Miklos Pless, Martin Brutsche, Swiss Group for Clinical Cancer Research
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/df9c71b1c1b54bdabc04d593f01a7ee1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/df9c71b1c1b54bdabc04d593f01a7ee1

Ejemplares similares